Work

Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity

Year: 2024

Type: article

Abstract: A BSTRACT Tyrosine kinase inhibitors (TKIs) have emerged as the preferred choice of treatment for various tumors as a result of better outcomes and quality of life without the debilitating side effects of cytotoxic chemotherapy. Erlotinib is a TKI against epidermal growth factor receptor that is commonly used in lung cancer and pancreatic cancer. The most common adverse effect expected is cutaneous toxicity, which occurs as acneiform rash. Here, we present a case of 71-year-old man with metastatic lung cancer who had an atypical squamous-crusted eruption with intense itching and pain on his forehead that resolved spontaneously after withholding erlotinib along with supportive care. The present case depicts unusual cutaneous toxicity with the use of TKI.

Source: Journal of Radiation and Cancer Research

DOI: 10.4103/jrcr.jrcr_12_24

Authors: Aashita, Vikas Yadav, Pragyat Thakur, Anuja Kapoor

Institutions: Vardhman Mahavir Medical College & Safdarjung Hospital, Homi Bhabha National Institute

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4404252234

FWCI:

Cites: 9

Cited by:

Related to: 10